Daunorubicin: Side Effects, Uses & Monitoring

Facts extracted from current FDA product labeling for Daunorubicin. Educational only — not medical advice.

Labeled uses

Daunorubicin hydrochloride injection in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.

Source: FDA labeling via NIH DailyMed (set 9705fa12…). Not affiliated with FDA or NIH.

Medical disclaimer: Always consult a qualified healthcare professional about any medication.

Ratings summarize government-reported measures — they don't capture your personal needs. Visit the facility, ask about staffing and services, and use CMS checklists. This profile is informational only and is not a recommendation.